- Kythera Biopharmaceuticals (NASDAQ:KYTH) announces the commercial availability of Kybella (deoxycholic acid) injection in the U.S. Kybella is the first and only FDA-approved non-surgical treatment for reducing submental fullness, commonly known as double chin.
- The cost to physicians will be $300 per vial or $1,200 for a four-vial pack. The average dose will be 2-3 vials per treatment session (4-6 mL) so patients will need a purse as ample as their extra chin. If the doctor's cost is $600 - 900, then the patient's cost will be a multiple of this.
- The company was just acquired by Allergan (AGN) for $75 per share or ~$2.1B.